KABIDARBA 40MG INJECTION contains Darbepoetin alfa which belongs to the group of medicines called Erythropoiesis-stimulating agents. It is used to manage symptomatic anemia associated with chronic renal failure (CRF) in adults and children. In kidney failure, the kidney does not produce enough erythropoietin (a natural hormone) which can often cause anemia.
Before KABIDARBA 40MG INJECTION management, your doctor may want you to take blood tests to measure how your anaemia is responding and may adjust your dose to maintain long-term control of your condition. Your blood pressure will also be checked regularly, especially at the beginning of your management.
KABIDARBA 40MG INJECTION is not recommended for use in patients having high blood pressure which is not being controlled. Before receiving KABIDARBA 40MG INJECTION, inform your doctor if you have or ever had high blood pressure which is being controlled with medicines, sickle cell anemia, fits, liver disease, lack of response to medicines used to manage anemia, latex allergy or hepatitis C.
KABIDARBA 40MG INJECTION should be used with caution in pregnant women. Patients must not breastfeed while receiving KABIDARBA 40MG INJECTION. No data is available regarding KABIDARBA 40MG INJECTION use in children (less than 1 month old) with CKD receiving and not receiving dialysis. The safety and efficacy of KABIDARBA 40MG INJECTION in children with cancer have not been established so, consult your child’s doctor for advice.
The most common side effects of receiving KABIDARBA 40MG INJECTION are high blood pressure, allergic reactions, pain around the area injected and rash or redness of the skin. Call your doctor if any of the symptoms worsen.
No content available
